TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Our work illuminates actionable metabolic features driven by the TFE3 fusion in tRCC that are distinct from other RCC subtypes, offering hope that molecularly-directed therapies can be advanced to specifically target the biology of this aggressive subtype of kidney cancer.